Although ocrelizumab-treated patients with multiple sclerosis (MS) were generally sicker, after adjusting for baseline characteristics, they were more likely to be employed and experienced less impact on work productivity than those treated with oral (teriflunomide, fingolimod or dimethyl fumarate) or injectable (interferon β-1a, interferon β-1b, glatiramer acetate or peginterferon β-1a) therapies.

Reductions in work productivity impairment may also lessen indirect costs to both patients with MS (through lost work) and their employers (through maintaining work productivity levels).

The association of work productivity with ocrelizumab therapy should be taken into consideration when choosing therapy for patients, particularly since the majority of patients with MS are younger adults of working age.